GE HealthCare Technologies Stock in Brief

By Scott Lee • Tuesday, June 13 12:49 • Permanent Link

GE HealthCare Technologies logged a -1.5% change during today's afternoon session, and is now trading at a price of $77.13 per share. The S&P 500 index moved 1.0%. GEHC's trading volume is 1,604,795 compared to the stock's average volume of 2,649,900.

GE HealthCare Technologies trades -16.53% away from its average analyst target price of $92.4 per share. The 5 analysts following the stock have set target prices ranging from $86.0 to $97.0, and on average have given GE HealthCare Technologies a rating of buy.

Anyone interested in buying GEHC should be aware of the facts below:

GE HealthCare Technologies's current price is 30.1% above its Graham number of $59.3, which implies that at its current valuation it does not offer a margin of safety
GE HealthCare Technologies has moved 30.4% over the last year, and the S&P 500 logged a change of 16.2%
Based on its trailing earnings per share of 3.73, GE HealthCare Technologies has a trailing 12 month Price to Earnings (P/E) ratio of 20.7 while the S&P 500 average is 15.97
GEHC has a forward P/E ratio of 17.9 based on its forward 12 month price to earnings (EPS) of $4.3 per share
Its Price to Book (P/B) ratio is 5.24 compared to its sector average of 6.23
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.
Based in Chicago, the company has 50,000 full time employees and a market cap of $35.07 Billion. GE HealthCare Technologies currently returns an annual dividend yield of 0.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.